Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL777971 | 0.98 | MAPT (0.56) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL7541817 | 0.93 | HTR2A (0.56) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL21615770 | 0.89 | HTR2A (0.46) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL2048495 | 0.89 | HTR2A (0.59) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL25432674 | 0.88 | ALDH1A1 (0.47) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL21795337 | 0.85 | MMP8 (0.44) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL21615541 | 0.84 | MMP8 (0.43) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL702657 | 0.84 | MMP8 (0.69) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL794908 | 0.84 | MMP8 (0.43) | MAPTHTR2AKCNH2HTR2CALDH1A1 | |
| SCHEMBL10797246 | 0.81 | HTR2A (0.46) | MAPTHTR2AKCNH2HTR2CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61231009-A | — | — | None | — | — | JP | disclosed |
| EP-4256347-B1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | HOFFMANN LA ROCHE (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-12100809-B2 | Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-24 | — | — | US | disclosed |
| US-11814348-B2 | Oxidizing liquid media for chemical transformations | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4256347-A1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20230314444-A1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-10-05 | — | — | US | disclosed |
| CN-116710783-A | Detection of target analytes by cross-spray ESI mass spectrometry | 豪夫迈·罗氏有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11396492-B2 | Direct oxidative amination of hydrocarbons | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2022-07-26 | — | — | US | disclosed |
| WO-2022117604-A1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| US-20220149436-A1 | NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2022-05-12 | — | — | US | disclosed |
| US-5948838-A | 0.01 TO 5 PARTS BY WEIGHT OF A COMPOUND CONTAINING OXYMETHYLENE UNIT | MITSUBISHI ENGINEERING-PLASTICS CORP. (JP) | 1999-09-07 | — | — | US | disclosed |
| WO-1999008987-A1 | CYCLOHEXENONE LONG-CHAIN ALCOHOL AND MEDICAMENT CONTAINING SAME | MEIJI MILK PRODUCTS CO., LTD. (JP) | 1999-02-25 | — | — | WO | disclosed |
| EP-0794218-A2 | Polycarbonate resin composition stabilized against radiation | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-09-10 | — | — | EP | disclosed |
| EP-0753540-A2 | Polycarbonate resin composition | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5372914-A | Pattern forming method | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-12-13 | — | — | US | disclosed |
| US-5348838-A | Photoresist | KABUSHIKI KAISHA TOSHIBA (JP) | 1994-09-20 | — | — | US | disclosed |
| US-4873278-A | Inhibition of irradiation yellowing in polysulfone compositions | GENERAL ELECTRIC COMPANY (US) | 1989-10-10 | — | — | US | disclosed |
| EP-0335758-A2 | Derivatives of 1-arylsulfonyl-2-pyrolidinone, process for their preparation, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1989-10-04 | — | — | EP | disclosed |
| EP-0142322-B1 | CYCLOHEXANE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-09 | — | — | EP | disclosed |
| JP-S61231009-A | PRODUCTION OF OLEFIN POLYMER | MITSUBISHI PETROCHEM CO LTD | 1986-10-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396492-B2 | Direct oxidative amination of hydrocarbons | GPX4, AOC2, NOX1 | MAPT 3348/4885HTR2A 2069/4885KCNH2 2085/4885 |
| US-11814348-B2 | Oxidizing liquid media for chemical transformations | HAO2, LPO, DUOX1 | MAPT 3739/4885HTR2A 2010/4885KCNH2 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.